G Bakris

Summary

Affiliation: Rush University Medical Center
Country: USA

Publications

  1. ncbi request reprint Rosiglitazone reduces urinary albumin excretion in type II diabetes
    G Bakris
    Rush University, Hypertension Clinical Research Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    J Hum Hypertens 17:7-12. 2003
  2. ncbi request reprint Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy
    G L Bakris
    Rush University Hypertension Center, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    Kidney Int 54:1283-9. 1998
  3. ncbi request reprint Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction
    George L Bakris
    Rush University Hypertension Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Curr Diab Rep 2:258-62. 2002
  4. ncbi request reprint Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 5:202-9. 2003
  5. ncbi request reprint ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 4:420-3. 2002
  6. ncbi request reprint Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals
    George L Bakris
    Departments of Preventive Medicine and Internal Medicine, Rush Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612, USA
    Postgrad Med 112:73-4, 77-80, 83-4. 2002
  7. ncbi request reprint Pathogenesis and clinical physiology of hypertension
    George L Bakris
    Rush University Hypertension Clinical Research Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, 1700 West Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Cardiol Clin 20:195-206, v. 2002
  8. ncbi request reprint Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease
    Jay P Garg
    Rush Presbyterian St Luke s Medical Center, Department of Preventive Medicine, Hypertensison Clinical Research Center, Chicago, IL 60612, USA
    Vasc Med 7:35-43. 2002
  9. ncbi request reprint The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols
    George L Bakris
    Deparments of Preventive Medicine and Internal Medicine, Rush Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612, USA
    Postgrad Med 113:35-40, 43-4, 50. 2003
  10. ncbi request reprint Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes
    Jay Garg
    Rush Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Curr Hypertens Rep 4:185-90. 2002

Collaborators

Detail Information

Publications74

  1. ncbi request reprint Rosiglitazone reduces urinary albumin excretion in type II diabetes
    G Bakris
    Rush University, Hypertension Clinical Research Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    J Hum Hypertens 17:7-12. 2003
    ..These findings suggest a potential beneficial effect of rosiglitazone in the treatment or prevention of renal and vascular complications of type II diabetes...
  2. ncbi request reprint Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy
    G L Bakris
    Rush University Hypertension Center, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    Kidney Int 54:1283-9. 1998
    ..Both angiotensin converting enzyme (ACE) inhibitors and the nondihydropyridine calcium antagonists, (non-DHPCAs) reduce both arterial pressure and proteinuria in those with diabetic nephropathy...
  3. ncbi request reprint Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction
    George L Bakris
    Rush University Hypertension Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Curr Diab Rep 2:258-62. 2002
    ..In this article we explore evidence for albuminuria being an integral component of the cardiometabolic syndrome and a risk factor for cardiovascular disease and stroke...
  4. ncbi request reprint Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 5:202-9. 2003
    ..A fixed-dose combination approach appears as safe as the current conventional approaches...
  5. ncbi request reprint ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 4:420-3. 2002
    ..This review critically evaluates the limited evidence in support of angiotensin-converting enzyme inhibitors as renal-protective agents in people with type 2 diabetes...
  6. ncbi request reprint Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals
    George L Bakris
    Departments of Preventive Medicine and Internal Medicine, Rush Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612, USA
    Postgrad Med 112:73-4, 77-80, 83-4. 2002
    ..This article describes current "best practice" guidance on appropriate treatment of high blood pressure in African Americans. Two patient scenarios offer insight into clinical strategies...
  7. ncbi request reprint Pathogenesis and clinical physiology of hypertension
    George L Bakris
    Rush University Hypertension Clinical Research Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, 1700 West Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Cardiol Clin 20:195-206, v. 2002
    ....
  8. ncbi request reprint Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease
    Jay P Garg
    Rush Presbyterian St Luke s Medical Center, Department of Preventive Medicine, Hypertensison Clinical Research Center, Chicago, IL 60612, USA
    Vasc Med 7:35-43. 2002
    ..Achieving such a goal with agents that also impact microalbuminuria will provide for a more complete cardiovascular risk reduction...
  9. ncbi request reprint The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols
    George L Bakris
    Deparments of Preventive Medicine and Internal Medicine, Rush Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612, USA
    Postgrad Med 113:35-40, 43-4, 50. 2003
    ..He describes their backing in research findings and outlines practical antihypertensive and renoprotective therapies to curtail risks of nephropathy and cardiovascular disease in patients with diabetes...
  10. ncbi request reprint Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes
    Jay Garg
    Rush Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Curr Hypertens Rep 4:185-90. 2002
    ..5 mg/dL, should be placed on an ACE inhibitor for cardiovascular risk reduction. If nephropathy is present, the evidence would support an ARB for therapy in concert with a b-blocker for cardiovascular risk reduction and renoprotection...
  11. ncbi request reprint The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial
    George L Bakris
    Rush Hypertension Center, Rush Medical Center, Suite 470, 1700 W Van Buren, Chicago, IL 60612, USA
    J Diabetes Complications 19:74-9. 2005
    ..The GEMINI trial, therefore, is the first large randomized trial to assess whether utilizing a third-generation beta-blocker yields a favorable metabolic profile in the patient with Type 2 diabetes and hypertension...
  12. ncbi request reprint A practical approach to achieving recommended blood pressure goals in diabetic patients
    G L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Rush University Hypertension Center, 1700 W Van Buren, Suite 470, Chicago, IL 60612, USA
    Arch Intern Med 161:2661-7. 2001
    ..A case study that applies these concepts in outpatient practice is included...
  13. ncbi request reprint Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors
    G L Bakris
    Rush University Hypertension Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    Kidney Int 56:206-10. 1999
    ..This lack of renoprotection may relate to nonspecific adrenergic stimulation by DA. The effect of select DA-1 receptor stimulation on renal hemodynamics following RCM administration has not been evaluated...
  14. ncbi request reprint Hypertension in patients with diabetes. Why is aggressive treatment essential?
    G Bakris
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    Postgrad Med 107:53-6, 61-4. 2000
    ..More aggressive treatment is needed to improve the prognosis for this over-expanding patient population...
  15. ncbi request reprint ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group
    G L Bakris
    Hypertension Clinical Research Center, Rush University, Chicago, Illinois 60612, USA
    Kidney Int 58:2084-92. 2000
    ..No study has evaluated the comparative effects of an angiotensin-converting enzyme (ACE) inhibitor versus an angiotensin receptor blocker (ARB) on the changes in serum [K(+)] in people with renal insufficiency...
  16. ncbi request reprint Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?
    G L Bakris
    Rush University Hypertension Clinical Research Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612, USA
    Arch Intern Med 160:685-93. 2000
    ..However, many physicians fail to use ACEIs or angiotensin receptor blockers in patients with renal insufficiency for fear that either serum creatinine or potassium levels will rise...
  17. doi request reprint Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
    George L Bakris
    Hypertensive Diseases Unit, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Lancet 375:1173-81. 2010
    ..We assessed the effects of these drug combinations on progression of chronic kidney disease...
  18. ncbi request reprint Choices and goals in the treatment of the diabetic hypertensive patient
    E Basta
    Rush Medical Center, 1700 W. Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Curr Hypertens Rep 3:387-91. 2001
    ..Combination therapy has been found to be very effective, and one arm should be an angiotensin converting enzyme inhibitor...
  19. ncbi request reprint Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study
    G Bakris
    Department of Preventive Medicine, Rush Presbyterian St. Luke's Medical Center, Chicago, IL, USA
    J Clin Hypertens (Greenwich) 3:16-21. 2001
    ..Both drugs were well tolerated. (c)2001 by Le Jacq...
  20. doi request reprint Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study
    I Lazich
    Hypertensive Diseases Unit, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Diabetes Obes Metab 14:181-6. 2012
    ..This study examines the effects of simvastatin combined with rosiglitazone on vascular inflammation, oxidant stress, ambulatory blood pressure (BP) and other atherosclerotic factors in patients with the metabolic syndrome...
  21. ncbi request reprint Atlas vertebra realignment and achievement of arterial pressure goal in hypertensive patients: a pilot study
    G Bakris
    Department of Preventive Medicine, Rush University Hypertension Center, Chicago, IL, USA
    J Hum Hypertens 21:347-52. 2007
    ..5 beats per minute, placebo). No adverse effects were recorded. We conclude that restoration of Atlas alignment is associated with marked and sustained reductions in BP similar to the use of two-drug combination therapy...
  22. ncbi request reprint Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action
    G Bakris
    Department of Medicine, Hypertensive Diseases Center, University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    J Hum Hypertens 22:63-70. 2008
    ..These actions should be pursued with vigour in accordance with current clinical guidelines, with the details of implementation adapted to the economic and cultural setting...
  23. ncbi request reprint Beta-blockers in the treatment of hypertension: new data, new directions
    Michael A Weber
    State University of New York, Downstate Medical College, 450 Clarkson Avenue, Brooklyn, NY 11023, USA
    J Clin Hypertens (Greenwich) 10:234-8. 2008
  24. doi request reprint Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study
    Sverre E Kjeldsen
    University of Michigan Health System, Ann Arbor, Michigan, USA
    Blood Press 17:7-17. 2008
    ..3%) and diabetic patients <130/80 mmHg (43.3%) at 12 months of follow-up than any other large outcomes trial. We have analyzed baseline predictors of BPs and BP control at 12 months...
  25. ncbi request reprint Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies
    Timothy R Smith
    Mercy Health Research, Washington University School of Medicine, St Louis, MO 63141, USA
    J Clin Hypertens (Greenwich) 9:355-64. 2007
    ..These findings were consistent with the primary efficacy analysis results from the overall study populations. Combination regimens were generally well tolerated by all patient subgroups...
  26. ncbi request reprint Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk
    Michael A Weber
    SUNY Downstate Medical College, 420 Lexington Avenue, Brooklyn, NY 10170, USA
    Blood Press 16:13-9. 2007
    ..It is noteworthy that the mean BMI of 31 in this cohort is clearly above the accepted diagnostic criterion of obesity and that 60% of patients are diabetic, possibly reflecting secular trends in clinical disease...
  27. ncbi request reprint ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression?
    George L Bakris
    J Clin Hypertens (Greenwich) 9:413-5. 2007
  28. ncbi request reprint Albuminuria and cardiovascular risk
    Zvezdana Bogojevic
    Rush University Medical Center, Chicago, IL 60612, USA
    Heart Fail Clin 2:53-9. 2006
  29. ncbi request reprint Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes
    George L Bakris
    Ann Intern Med 148:400-1. 2008
  30. ncbi request reprint Antihypertensive therapy in the presence of proteinuria
    Pantelis A Sarafidis
    Hypertension Clinical Research Center, Department of Preventive Medicine, Rush University Medical Center, Chicago, IL, USA
    Am J Kidney Dis 49:12-26. 2007
    ....
  31. ncbi request reprint Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, NY, USA
    J Clin Hypertens (Greenwich) 8:840-9. 2006
    ..Adverse events, including clinical chemistry values, were similar in the drug-treated and placebo groups. Carvedilol CR has a clinically meaningful defined dose-dependent antihypertensive effect that persists throughout a 24-hour period...
  32. ncbi request reprint Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile
    George L Bakris
    Hypertension Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Am J Cardiol 98:46L-52L. 2006
    ..These will be the first head-to-head trials using carvedilol CR to determine whether the differing pharmacologic actions among beta-blockers result in varying effects on cardiovascular risk factors...
  33. ncbi request reprint Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST])
    Rhonda Cooper-DeHoff
    University of Florida College of Medicine, Gainesville, Florida, USA
    Am J Cardiol 98:890-4. 2006
    ....
  34. ncbi request reprint Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP)
    Peter A McCullough
    Division of Cardiology, William Beaumont Hospital, Royal Oak, MI 48073, USA
    Arch Intern Med 167:1122-9. 2007
    ..We hypothesized that each of these chronic kidney disease-related measures would have an independent relationship with CVD...
  35. ncbi request reprint Body weight changes with beta-blocker use: results from GEMINI
    Franz H Messerli
    St Luke s Roosevelt Hospital Center, New York City, NY 10019, USA
    Am J Med 120:610-5. 2007
    ....
  36. doi request reprint Hypertension awareness, treatment, and control in chronic kidney disease
    Pantelis A Sarafidis
    Hypertensive Diseases Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Am J Med 121:332-40. 2008
    ..The objective of this study was to determine the state of blood pressure control in patients with chronic kidney disease...
  37. doi request reprint Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy
    George Bakris
    Department of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
    Kidney Int 74:364-9. 2008
    ..We conclude that telmisartan is superior to losartan in reducing proteinuria in hypertensive patients with diabetic nephropathy, despite a similar reduction in blood pressure...
  38. ncbi request reprint Comparative efficacy of two different beta-blockers on 24-hour blood pressure control
    Pantelis Sarafidis
    Rush University Hypertension Clinical Research Center, Department of Preventive Medicine, Chicago, IL, USA
    J Clin Hypertens (Greenwich) 10:112-8. 2008
    ..It is possible that differences in outcome between atenolol-based and other therapies may be the result of inadequate dosing of atenolol, a medication that may not be effective for the entire 24-hour period...
  39. ncbi request reprint Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?
    Matthew R Weir
    Division of Nephrology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Clin Hypertens (Greenwich) 10:146-52. 2008
    ..Studies are now under way to determine the relative benefits of an RAAS blocker/diuretic compared with an RAAS blocker/calcium channel blocker as initial therapy...
  40. pmc Slowing nephropathy progression: focus on proteinuria reduction
    George L Bakris
    Hypertensive Diseases Unit, Section of Endocrinology, Diabetes and Metabolism, Pritzker School of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Clin J Am Soc Nephrol 3:S3-10. 2008
    ..These agents also reduce proteinuria, a risk marker for renal disease progression. Accumulating evidence indicates that their antiproteinuric effect correlates with their additional renal benefits...
  41. ncbi request reprint Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker
    George L Bakris
    University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 10:27-32. 2008
    ..The combination of amlodipine and an angiotensin II receptor blocker is well tolerated, including in patients with stage 2 hypertension and the elderly...
  42. ncbi request reprint Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial
    Jackson T Wright
    Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
    J Clin Hypertens (Greenwich) 9:842-9. 2007
    ..The use of carvedilol compared with metoprolol did not effect glycemic control...
  43. ncbi request reprint Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study
    Henry R Black
    New York University School of Medicine, New York, NY 10016, USA
    J Clin Hypertens (Greenwich) 9:760-9. 2007
    ....
  44. ncbi request reprint Exceptional early blood pressure control rates: the ACCOMPLISH trial
    Kenneth Jamerson
    University of Michigan Health System, Division of Cardiovascular Medicine, Ann Arbor, Michigan 48106 0739, USA
    Blood Press 16:80-6. 2007
    ..At baseline, 97% of subjects were treated with anti-hypertensive medication at entry, but only 37% of participants had blood pressure (BP) control (<140/90 mmHg). Single-tablet combination therapy may improve control rates...
  45. ncbi request reprint The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension
    Luis Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Blood Press 16:72-9. 2007
    ....
  46. ncbi request reprint Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria
    George L Bakris
    Rush University Medical Center, Chicago, Illinois 60612, USA
    J Hypertens 24:2047-55. 2006
    ..To test the hypothesis that rosiglitazone combined with metformin provides a greater reduction in microalbuminuria and blood pressure than metformin and glyburide at comparable levels of glycemic control...
  47. ncbi request reprint Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial
    Franz H Messerli
    St Luke s Roosevelt Hospital Center, New York, NY 10019, USA
    J Clin Hypertens (Greenwich) 8:571-81; quiz 582-3. 2006
    ..Concomitant administration of amlodipine and atorvastatin is an effective and well tolerated treatment for coexisting hypertension and dyslipidemia...
  48. ncbi request reprint The importance of blood pressure control in the patient with diabetes
    George L Bakris
    Departments of Preventative and Internal Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    Am J Med 116:30S-38S. 2004
    ..The new beta-blockers may play an important role in achieving blood pressure goals...
  49. ncbi request reprint What have we learned from the current trials?
    Kevin C Abbott
    Nephrology Service, Walter Reed Army Medical Center, 6900 Georgia Avenue, Building 2, Ward 48, Washington, DC 20307 5001, USA
    Med Clin North Am 88:189-207. 2004
    ..Based on the results of the AASK trial, the authors add the same for the use of ACE inhibitors in African Americans...
  50. ncbi request reprint Diabetes and chronic kidney disease: tragedy and challenge
    Dave Y Chua
    Department of Preventive Medicine, Rush University Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    Blood Purif 22:130-5. 2004
    ....
  51. ncbi request reprint A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial
    Carl J Pepine
    Division of Cardiovascular Medicine, Department of Medicine, University of Florida College of Medicine, Gainesville 32610, USA
    JAMA 290:2805-16. 2003
    ..Despite evidence of efficacy of antihypertensive agents in treating hypertensive patients, safety and efficacy of antihypertensive agents for coronary artery disease (CAD) have been discerned only from subgroup analyses in large trials...
  52. ncbi request reprint Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, NY 11203, USA
    J Clin Hypertens (Greenwich) 5:322-9. 2003
    ..001 for each) with the increases in the GWBI scores. Controlling blood pressure appears to be an important element in improving subjective health perceptions of hypertensive patients...
  53. ncbi request reprint Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK)
    Garabed Eknoyan
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Am J Kidney Dis 42:617-22. 2003
  54. ncbi request reprint Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Rush Medical College, Chicago, IL 60612, USA
    Arch Intern Med 163:1555-65. 2003
    ..Clinical trials of nephropathy in people with type 2 diabetes mellitus have not examined the effects of systolic blood pressure (SBP) or pulse pressure (PP) on the time to end-stage renal disease (ESRD) or death...
  55. ncbi request reprint The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report
    Aram V Chobanian
    Department of Medicine, Boston University School of Medicine, Boston, Mass, USA
    JAMA 289:2560-72. 2003
    ..Empathy builds trust and is a potent motivator. Finally, in presenting these guidelines, the committee recognizes that the responsible physician's judgment remains paramount...
  56. ncbi request reprint Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks
    Janice G Douglas
    Case Western Reserve University, Department of Medicine, Room W 165, 10900 Euclid Ave, Cleveland, Ohio 44106, USA
    Arch Intern Med 163:525-41. 2003
  57. ncbi request reprint Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcome
    James R Sowers
    Departments of Medicine, Biochemistry, and Cell Biology, State University of New York Health Science Center, Brooklyn College of Medicine, Brooklyn, NY 11203, USA
    Postgrad Med 112:24-6, 29-30, 33-4 passim. 2002
    ..In this article, Drs Sowers, Ferdinand, Bakris, and Douglas examine the biologic, social, and genetic factors that contribute to these health disparities, the risk for which appears in early childhood...
  58. ncbi request reprint Hypertension and diabetes: family physicians' pivotal role
    George L Bakris
    Am Fam Physician 66:1151-2. 2002
  59. ncbi request reprint Evaluation and treatment of patients with systemic hypertension
    Jay Garg
    Rush University Hypertension Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    Circulation 105:2458-61. 2002
  60. ncbi request reprint Blood pressure control and nephroprotection in diabetes
    Kevin Abbott
    Walter Reed Army Hospital, Department of Medicine, Division of Nephrology, Bethesda, Maryland, USA
    J Clin Pharmacol 44:431-8. 2004
    ..Physicians need to work harder and educate patients on the importance of achieving these lower blood pressure guidelines...
  61. ncbi request reprint Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResi├│n Arterial en DIab├ęticos tipo Dos) study
    Luis M Ruilope
    Hypertension Unit, Hospital 12 du Octubre, Madrid, Spain
    J Hypertens 22:217-22. 2004
    ....
  62. ncbi request reprint Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes
    James R Sowers
    University of Missouri Columbia and Harry S Truman VA Medical Center, 65212, USA
    J Clin Hypertens (Greenwich) 8:470-80. 2006
    ..Irbesartan/HCTZ fixed combinations achieved SBP goals in over half of the T2DM patients and nearly three quarters of patients with the metabolic syndrome, with SBP uncontrolled on antihypertensive monotherapy...
  63. ncbi request reprint Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension?
    Panteleimon A Sarafidis
    1st Department of Preventive Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Greece
    J Clin Hypertens (Greenwich) 8:351-6; quiz 357-8. 2006
    ....
  64. ncbi request reprint Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes
    George L Bakris
    Rush University Medical Center, Chicago, IL 60612, USA
    Hypertension 46:1309-15. 2005
    ..These differences cannot be explained by effects on blood pressure or alpha1-antagonism but may relate to antioxidant properties of carvedilol...
  65. ncbi request reprint The effect of ruboxistaurin on nephropathy in type 2 diabetes
    Katherine R Tuttle
    Research Department, The Heart Institute and Sacred Heart Medical Center, Spokane, WA 99204 2340, USA
    Diabetes Care 28:2686-90. 2005
    ..Ruboxistaurin selectively inhibits protein kinase C-beta and ameliorates kidney disease in animal models of diabetes. The purpose of this study was to evaluate the effects of ruboxistaurin on diabetic nephropathy in humans...
  66. ncbi request reprint Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes
    Nathaniel Winer
    SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
    Prev Cardiol 8:87-92. 2005
    ..05). No significant change in small-vessel compliance was observed with either treatment. Greater improvement in large-vessel compliance with combination therapy was independent of BP lowering...
  67. ncbi request reprint The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension
    Janice Lea
    Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
    Arch Intern Med 165:947-53. 2005
    ..The objective of this study was to relate baseline and early changes in proteinuria and glomerular filtration rate (GFR) to long-term progression of hypertensive nondiabetic kidney disease...
  68. ncbi request reprint Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Ill, USA
    JAMA 292:2227-36. 2004
    ..Beta-blockers have been shown to decrease cardiovascular risk in patients with hypertension and type 2 diabetes mellitus (DM); however, some components of the metabolic syndrome are worsened by some beta-blockers...
  69. ncbi request reprint Slowing the progression of diabetic nephropathy and its cardiovascular consequences
    Peter A McCullough
    Division of Nutritional and Preventive Medicine, William Beaumont Hospital, Beaumont Health Center, 4949 Coolidge, Royal Oak, MI 48073, USA
    Am Heart J 148:243-51. 2004
    ..The goal of an ideal clinical trial would be ESRD prevention; however, pragmatic objectives such as a greater understanding of therapeutic toxicities should also be explored in this population...
  70. ncbi request reprint The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy
    Jonathan C Fox
    Merck Research Laboratories, BLX 21, P O Box 4, West Point, PA 19486, USA
    J Clin Hypertens (Greenwich) 6:437-42; quiz 443-4. 2004
    ..The use of two medications will achieve goal BP in more patients than monotherapy. This observation is important in treatment of high-risk patients with diabetes...
  71. ncbi request reprint Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma School of Medicine, Oklahoma City, Oklahoma 73132, USA
    Am J Hypertens 17:590-6. 2004
    ....
  72. ncbi request reprint The role of calcium antagonists in chronic kidney disease
    Casey N Gashti
    Rush University Hypertension Clinical Research Centre, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Centre, Chicago, Illinois 60612, USA
    Curr Opin Nephrol Hypertens 13:155-61. 2004
    ..To review goals of antihypertensive treatment in chronic kidney disease in the context of what role calcium antagonists play toward reducing progression of kidney disease...
  73. ncbi request reprint Management of hypertension in the cardiometabolic syndrome and diabetes
    Nitin Khosla
    Rush University Hypertension Center, Rush University Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Curr Diab Rep 4:199-205. 2004
    ..Thus, treating the cardiometabolic syndrome requires an aggressive approach with a focus on both lifestyle modification and pharmacologic intervention...
  74. ncbi request reprint Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options
    Domenic A Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 1060, USA
    J Clin Hypertens (Greenwich) 4:52-7. 2002
    ..An evidence-based therapeutic approach derived from these trials would argue for ARBs to be the foundation of therapy in the patient with type 2 diabetes and nephropathy...